0.7099 USD
-0.0133
1.84%
At close Apr 1, 4:00 PM EDT
1 day
-1.84%
5 days
-20.21%
1 month
-28.83%
3 months
-47.41%
6 months
-78.55%
Year to date
-47.41%
1 year
-88.82%
5 years
-95.54%
10 years
-98.86%
 

About: Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Employees: 78

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $14K | Put options by funds: $7K

2.94% less ownership

Funds ownership: 21.35% [Q3] → 18.4% (-2.94%) [Q4]

8% less funds holding

Funds holding: 40 [Q3] → 37 (-3) [Q4]

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

69% less capital invested

Capital invested by funds: $10.9M [Q3] → $3.37M (-$7.54M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for AFMD.

Financial journalist opinion

Neutral
GlobeNewsWire
6 days ago
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois.
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
Neutral
GlobeNewsWire
4 weeks ago
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 at 2:20 p.m. Eastern Daylight Time.
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Neutral
GlobeNewsWire
3 months ago
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the oral presentation of data on AFM28 at the 66th ASH Annual Meeting and Exposition. The data, derived from the first-in-human Phase 1 study of AFM28, showed promising results in R/R AML, with signs of clinical efficacy and a well-managed safety profile at doses up to 300 mg weekly.
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Neutral
GlobeNewsWire
3 months ago
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer.
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Neutral
GlobeNewsWire
3 months ago
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
MANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a poster session at the 66th ASH Annual Meeting and Exposition. The dataset includes 22 patients from the run-in phase of the LuminICE-203 (AFM13-203) phase 2 open-label, multicenter, multi-cohort study. The trial evaluates the safety and efficacy of the combination of acimtamig (AFM13) with Artiva Biotherapeutics' allogeneic NK cell AlloNK® in patients with R/R cHL.
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Negative
Zacks Investment Research
3 months ago
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Affimed's acimtamig in combination with AlloNK for treating Hodgkin lymphoma. Shares fall.
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
Neutral
GlobeNewsWire
3 months ago
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Neutral
Seeking Alpha
4 months ago
Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
Affimed N.V. (NASDAQ:AFMD ) Q3 2024 Earnings Call Transcript November 14, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations & Director of Investor Relations Shawn Leland - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Michael Wolf - Head of Finance & Administration Conference Call Participants Li Watsek - Cantor Daina Graybosch - Leerink Partners Yanan Zhu - Wells Fargo Li Chen - HC Wainright Yale Jen - Laidlaw & Company Dara Azar - Stifel Operator Good day, everyone.
Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
Affimed Reports Third Quarter 2024 Financial Results & Business Update
MANNHEIM, Germany, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the quarter ended September 30, 2024.
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Neutral
GlobeNewsWire
4 months ago
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Charts implemented using Lightweight Charts™